Polymorphisms in the H19 Gene and the Risk of Bladder Cancer

European Urology

Volumn 54, Issue 5, 2008, Pages 1118-1126

  Verhaegh, Gerald W ^a,b   Verkleij, Linda ^a   Vermeulen, Sita H H M ^a   den Heijer, Martin ^a   Witjes, J Alfred ^a   Kiemeney, Lambertus A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder cancer; H19 gene; Non coding RNA; Single nucleotide polymorphisms; Susceptibility

Indexed keywords

RNA;

ALLELE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; GENE; GENE ACTIVATION; GENE LOCUS; GENOTYPE; H19 GENE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; PROGNOSIS; RISK FACTORS; RNA, UNTRANSLATED; URINARY BLADDER NEOPLASMS;

EID: 55649105852     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.060     Document Type: Article

References (29)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Silverman D.T., Devesa S.S., Moore L.E., and Rothman N. Bladder cancer. In: Schottenfeld D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention (2006), Oxford University Press, New York 1101-1127
3. Kiemeney L.A. Familial bladder cancer. In: Lerner S.P., Schoenberg M., and Sternberg C. (Eds). Textbook of bladder cancer (2005), Taylor & Francis - Informa, London 19-26
4. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (2005) 4-34
5. Wu X., Gu J., Grossman H.B., et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78 (2006) 464-479
6. Brannan C.I., Dees E.C., Ingram R.S., and Tilghman S.M. The product of the H19 gene may function as an RNA. Mol Cell Biol 10 (1990) 28-36
7. Poirier F., Chan C.T., Timmons P.M., Robertson E.J., Evans M.J., and Rigby P.W. The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo. Development 113 (1991) 1105-1114
8. Zhang Y., and Tycko B. Monoallelic expression of the human H19 gene. Nat Genet 1 (1992) 40-44
9. Ariel I., Lustig O., Schneider T., et al. The imprinted H19 gene as a tumor marker in bladder carcinoma. Urology 45 (1995) 335-338
10. Ariel I., Ayesh S., Perlman E.J., et al. The product of the imprinted H19 gene is an oncofetal RNA. Mol Pathol 50 (1997) 34-44
11. Cooper M.J., Fischer M., Komitowski D., et al. Developmentally imprinted genes as markers for bladder tumor progression. J Urol 155 (1996) 2120-2127
12. Elkin M., Shevelev A., Schulze E., et al. The expression of the imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 374 (1995) 57-61
13. Ariel I., Sughayer M., Fellig Y., et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 53 (2000) 320-323
14. Lottin S., Adriaenssens E., Dupressoir T., et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis 23 (2002) 1885-1895
15. Ayesh S., Matouk I., Schneider T., et al. Possible physiological role of H19 RNA. Mol Carcinog 35 (2002) 63-74
16. Barsyte-Lovejoy D., Lau S.K., Boutros P.C., et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66 (2006) 5330-5337
17. Reik W., and Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet 2 (2001) 21-32
18. Takai D., Gonzales F.A., Tsai Y.C., Thayer M.J., and Jones P.A. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet 10 (2001) 2619-2626
19. Kondo M., Suzuki H., Ueda R., et al. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene 10 (1995) 1193-1198
20. Takeuchi S., Hofmann W.K., Tsukasaki K., et al. Loss of H19 imprinting in adult T-cell leukaemia/lymphoma. Br J Haematol 137 (2007) 380-381
21. The International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-96.
22. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
23. Purcell S., Daly M.J., and Sham P.C. WHAP: haplotype-based association analysis. Bioinformatics 23 (2007) 255-256
24. Petry C.J., Ong K.K., Barratt B.J., et al. Common polymorphism in H19 associated with birthweight and cord blood IGF-II levels in humans. BMC Genet 6 (2005) 22
25. Wilkin F., Paquette J., Ledru E., Hamelin C., Pollak M., and Deal C.L. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 267 (2000) 4020-4027
26. Li S.L., Goko H., Xu Z.D., et al. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 291 (1998) 469-479
27. Aidoo M., Terlouw D.J., Kolczak M.S., et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 359 (2002) 1311-1312
28. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5 (2005) 713-725
29. Mattick J.S., and Makunin I.V. Non-coding RNA. Hum Mol Genet 15 (2006) R17-R29